Cantor Fitzgerald Comments on ZVRA FY2025 Earnings

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Equities researchers at Cantor Fitzgerald issued their FY2025 earnings estimates for Zevra Therapeutics in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst L. Chen forecasts that the company will earn $1.88 per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $25.00 target price on the stock. The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.95) per share.

A number of other equities analysts have also recently issued reports on the company. Guggenheim started coverage on Zevra Therapeutics in a report on Monday, October 7th. They issued a “buy” rating and a $20.00 target price on the stock. Canaccord Genuity Group lowered their target price on shares of Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating on the stock in a report on Thursday, November 14th. Finally, HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of Zevra Therapeutics in a research note on Wednesday, November 20th. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $21.57.

Zevra Therapeutics Price Performance

NASDAQ:ZVRA opened at $8.15 on Thursday. The firm has a fifty day simple moving average of $8.66 and a two-hundred day simple moving average of $7.83. The company has a debt-to-equity ratio of 0.84, a quick ratio of 2.88 and a current ratio of 2.88. Zevra Therapeutics has a 12 month low of $4.20 and a 12 month high of $9.76.

Zevra Therapeutics (NASDAQ:ZVRA) last released its earnings results on Tuesday, November 12th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.25). The business had revenue of $3.70 million for the quarter, compared to analyst estimates of $5.04 million. Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. During the same period in the prior year, the business earned ($0.40) EPS.

Institutional Investors Weigh In On Zevra Therapeutics

A number of hedge funds have recently made changes to their positions in the business. FMR LLC boosted its position in shares of Zevra Therapeutics by 282,687.5% in the third quarter. FMR LLC now owns 2,313,202 shares of the company’s stock valued at $16,054,000 after acquiring an additional 2,312,384 shares during the period. Stonepine Capital Management LLC bought a new position in Zevra Therapeutics in the 3rd quarter worth about $4,858,000. Vestal Point Capital LP purchased a new stake in shares of Zevra Therapeutics in the 3rd quarter valued at about $3,644,000. Propel Bio Management LLC bought a new stake in shares of Zevra Therapeutics during the 3rd quarter valued at about $1,248,000. Finally, Geode Capital Management LLC grew its holdings in shares of Zevra Therapeutics by 14.2% during the third quarter. Geode Capital Management LLC now owns 1,043,864 shares of the company’s stock worth $7,246,000 after purchasing an additional 129,600 shares in the last quarter. 35.03% of the stock is currently owned by institutional investors.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.